venBio Global Strategic Fund IV, L.P.

10% owner

venBio Global Strategic Fund IV, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Attovia Therapeutics, Inc. Common Stock (ATTO). Across 1 priced purchase filing, the average 21-session return was +9.8% from execution and +17.3% from disclosure (delay-adjusted; derived). The largest single filing was $6.5M of ATTO (382,352 sh × $17.00, as filed), executed Aug 6.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+9.8%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+17.3%

same 1 filings, from disclosure

Filings, ttm

1 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$6.5M

shares × price, as filed

Last traded

Aug 6

Filed Aug 10

Open performance→

Volume by month

Buys $6.5M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names

ATTO

Attovia Therapeutics, Inc. Common Stock ATTO · 1 buy · 0 sells 1 filing

Recent filings

ATTOPURCHASE Attovia Therapeutics, Inc. Common Stock View filing → $6.5M
382,352 sh × $17.00
Exec Aug 6
Filed Aug 10 · 4:12 PM ET